HYAL1 hyaluronidase in prostate cancer: a tumor promoter and suppressor - PubMed (original) (raw)
HYAL1 hyaluronidase in prostate cancer: a tumor promoter and suppressor
Vinata B Lokeshwar et al. Cancer Res. 2005.
Abstract
Hyaluronidases degrade hyaluronic acid, which promotes metastasis. HYAL1 type hyaluronidase is an independent prognostic indicator of prostate cancer progression and a biomarker for bladder cancer. However, it is controversial whether hyaluronidase (e.g., HYAL1) functions as a tumor promoter or as a suppressor. We stably transfected prostate cancer cells, DU145 and PC-3 ML, with HYAL1-sense (HYAL1-S), HYAL1-antisense (HYAL1-AS), or vector DNA. HYAL1-AS transfectants were not generated for PC-3 ML because it expresses little HYAL1. HYAL1-S transfectants produced < or = 42 milliunits (moderate overproducers) or > or = 80 milliunits hyaluronidase activity (high producers). HYAL1-AS transfectants produced <10% hyaluronidase activity when compared with vector transfectants (18-24 milliunits). Both blocking HYAL1 expression and high HYAL1 production resulted in a 4- to 5-fold decrease in prostate cancer cell proliferation. HYAL1-AS transfectants had a G2-M block due to decreased cyclin B1, cdc25c, and cdc2/p34 expression and cdc2/p34 kinase activity. High HYAL1 producers had a 3-fold increase in apoptotic activity and mitochondrial depolarization when compared with vector transfectants and expressed activated proapoptotic protein WOX1. Blocking HYAL1 expression inhibited tumor growth by 4- to 7-fold, whereas high HYAL1 producing transfectants either did not form tumors (DU145) or grew 3.5-fold slower (PC-3 ML). Whereas vector and moderate HYAL1 producers generated muscle and blood vessel infiltrating tumors, HYAL1-AS tumors were benign and contained smaller capillaries. Specimens of high HYAL1 producers were 99% free of tumor cells. This study shows that, depending on the concentration, HYAL1 functions as a tumor promoter and as a suppressor and provides a basis for anti-hyaluronidase and high-hyaluronidase treatments for cancer.
Similar articles
- HYAL1 hyaluronidase: a molecular determinant of bladder tumor growth and invasion.
Lokeshwar VB, Cerwinka WH, Lokeshwar BL. Lokeshwar VB, et al. Cancer Res. 2005 Mar 15;65(6):2243-50. doi: 10.1158/0008-5472.CAN-04-2805. Cancer Res. 2005. PMID: 15781637 - HYAL1-v1, an alternatively spliced variant of HYAL1 hyaluronidase: a negative regulator of bladder cancer.
Lokeshwar VB, Estrella V, Lopez L, Kramer M, Gomez P, Soloway MS, Lokeshwar BL. Lokeshwar VB, et al. Cancer Res. 2006 Dec 1;66(23):11219-27. doi: 10.1158/0008-5472.CAN-06-1121. Cancer Res. 2006. PMID: 17145867 - Hyaluronic acid synthase-1 expression regulates bladder cancer growth, invasion, and angiogenesis through CD44.
Golshani R, Lopez L, Estrella V, Kramer M, Iida N, Lokeshwar VB. Golshani R, et al. Cancer Res. 2008 Jan 15;68(2):483-91. doi: 10.1158/0008-5472.CAN-07-2140. Cancer Res. 2008. PMID: 18199543 - Hyaluronan metabolism: a major paradox in cancer biology.
Stern R. Stern R. Pathol Biol (Paris). 2005 Sep;53(7):372-82. doi: 10.1016/j.patbio.2004.12.021. Epub 2005 Jan 19. Pathol Biol (Paris). 2005. PMID: 16085113 Review. - Clinical Applications of Hyaluronidase.
Weber GC, Buhren BA, Schrumpf H, Wohlrab J, Gerber PA. Weber GC, et al. Adv Exp Med Biol. 2019;1148:255-277. doi: 10.1007/978-981-13-7709-9_12. Adv Exp Med Biol. 2019. PMID: 31482503 Review.
Cited by
- Purification and characterization of the produced hyaluronidase by Brucella Intermedia MEFS for antioxidant and anticancer applications.
Ebraheem MA, El-Fakharany EM, Husseiny SM, Mohammed FA. Ebraheem MA, et al. Microb Cell Fact. 2024 Jul 18;23(1):200. doi: 10.1186/s12934-024-02469-z. Microb Cell Fact. 2024. PMID: 39026213 Free PMC article. - Targeting BET Proteins Decreases Hyaluronidase-1 in Pancreatic Cancer.
Kumar K, Kanojia D, Bentrem DJ, Hwang RF, Butchar JP, Tridandapani S, Munshi HG. Kumar K, et al. Cells. 2023 May 27;12(11):1490. doi: 10.3390/cells12111490. Cells. 2023. PMID: 37296612 Free PMC article. - In vitro contraceptive activities, molecular docking, molecular dynamics, MM-PBSA, non-covalent interaction and DFT studies of bioactive compounds from Aegle marmelos. Linn., leaves.
Gunasekaran P, Velmurugan Y, Arputharaj DS, Savaridasson JK, Hemamalini M, Venkatachalam R. Gunasekaran P, et al. Front Chem. 2023 Jan 26;11:1096177. doi: 10.3389/fchem.2023.1096177. eCollection 2023. Front Chem. 2023. PMID: 36778035 Free PMC article. - Enzyme and Reactive Oxygen Species-Responsive Dual-Drug Delivery Nanocomplex for Tumor Chemo-Photodynamic Therapy.
Xie Q, Gao S, Tian R, Wang G, Qin Z, Chen M, Zhang W, Wen Q, Ma Q, Zhu L. Xie Q, et al. Int J Nanomedicine. 2023 Jan 4;18:1-16. doi: 10.2147/IJN.S393862. eCollection 2023. Int J Nanomedicine. 2023. PMID: 36632237 Free PMC article. - Identification of a Small Molecule Inhibitor of Hyaluronan Synthesis, DDIT, Targeting Breast Cancer Cells.
Karalis T, Shiau AK, Gahman TC, Skandalis SS, Heldin CH, Heldin P. Karalis T, et al. Cancers (Basel). 2022 Nov 25;14(23):5800. doi: 10.3390/cancers14235800. Cancers (Basel). 2022. PMID: 36497283 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
Research Materials
Miscellaneous